- Conditions
- Osteogenesis Imperfecta (OI)
- Interventions
- Denosumab, Alternative osteoporosis medications
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced May 22, 2026, 2:44 AM EDT